Hyperion Defi (HYPD) Non-Current Deffered Revenue (2018 - 2022)
Hyperion Defi (HYPD) posted quarterly Non-Current Deffered Revenue of $60540.0 for Q3 2022, up 132.32% year-over-year from $26059.0 in Q3 2021, and up 347.52% quarter-over-quarter from $13528.0 in Q2 2022.
Hyperion Defi (HYPD) Non-Current Deffered Revenue (2018 - 2022) Analysis & Trends
Hyperion Defi (HYPD) has reported Non-Current Deffered Revenue for 5 consecutive years, with $60540.0 the latest figure, recorded in Q3 2022.
- In Q3 2022, Non-Current Deffered Revenue rose 132.32% year-over-year to $60540.0; the TTM figure through Sep 2022 stood at $60540.0 (up 132.32% YoY), while the FY2021 annual figure was $19949.0, down 48.43% from the prior year.
- Non-Current Deffered Revenue advanced to $60540.0 in Q3 2022 per HYPD's latest filing, from $13528.0 in the prior quarter.
- Across five years, Non-Current Deffered Revenue topped out at $60540.0 in Q3 2022 and bottomed at $2332.0 in Q3 2018.
- Historically, Non-Current Deffered Revenue has averaged $35285.9 across 5 years, with a median of $38684.0 in 2020.
- Annual changes were most pronounced in 2019 — Non-Current Deffered Revenue soared 1844.85% — and 2022, when it tumbled 64.05%.
- Hyperion Defi's Non-Current Deffered Revenue stood at $41584.0 in 2018, then rose by 9.06% to $45351.0 in 2019, then slipped by 14.7% to $38684.0 in 2020, then tumbled by 48.43% to $19949.0 in 2021, then jumped by 203.47% to $60540.0 in 2022.
- Business Quant data shows HYPD's Non-Current Deffered Revenue at $60540.0 in Q3 2022, $13528.0 in Q2 2022, and $15080.0 in Q1 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 147.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Hyperion Defi | 44.93 Mn | 35.29 Mn | 357,693.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2022 | 60,540.00 |
| Jun 30, 2022 | 13,528.00 |
| Mar 31, 2022 | 15,080.00 |
| Dec 31, 2021 | 19,949.00 |
| Sep 30, 2021 | 26,059.00 |
| Jun 30, 2021 | 37,632.00 |
| Mar 31, 2021 | 38,634.00 |
| Dec 31, 2020 | 38,684.00 |
| Sep 30, 2020 | 36,423.00 |
| Jun 30, 2020 | 45,345.00 |
| Mar 31, 2020 | 45,348.00 |
| Dec 31, 2019 | 45,351.00 |
| Sep 30, 2019 | 45,354.00 |
| Jun 30, 2019 | 44,817.00 |
| Mar 31, 2019 | 43,200.00 |
| Dec 31, 2018 | 41,584.00 |
| Sep 30, 2018 | 2,332.00 |